• In June 2026, UroGen Pharma Ltd. and UroGen Pharma Inc. announced a settlement and license agreement with Teva Pharmaceuticals resolving their U.S. patent litigation over Jelmyto, granting Teva a non-exclusive license to sell a generic version from 15 September 2030, subject to FDA approval and regulatory review.
• This agreement reduces legal uncertainty around UroGen’s key urothelial cancer therapy while defining a clear timeline for eventual generic competition.
• We’ll now examine how resolving Jelmyto’s patent dispute and setting a 2030 generic entry date could influence UroGen Pharma’s investment narrative.

Find 47 companies with promising cash flow potential yet trading below their fair value.

UroGen Pharma Investment Narrative Recap

To own UroGen Pharma, you need to be comfortable with a focused cancer franchise built around RTGel technology, ongoing net losses, and heavy investment in commercialization and late stage trials. The Teva settlement clarifies when Jelmyto may face U.S. generic competition, but with a 2030 date it does not materially change the near term focus on ZUSDURI uptake and funding risk from continued cash burn.

The most relevant recent update alongside the Teva deal is UroGen’s new US$250,000,000 term loan with Pharmakon, which refinanced prior debt and bolstered liquidity. Together, clearer Jelmyto patent visibility and added debt capacity frame the next few years as a test of whether ZUSDURI and UGN 103 can scale quickly enough to offset ongoing operating losses and reduce reliance on additional external capital.

Yet against this clearer patent runway, investors should still weigh the possibility that concentrated product risk could...

UroGen Pharma's narrative projects $536.0 million revenue and $173.1 million earnings by 2029. This requires 69.6% yearly revenue growth and about a $326.6 million earnings increase from -$153.5 million today.

Uncover how UroGen Pharma's forecasts yield a $36.11 fair value, a 33% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were already cautious, assuming UroGen would need roughly US$538,600,000 in 2029 revenue and US$183,700,000 in earnings, so you should expect that the Jelmyto settlement, funding needs, and regulatory risks could all shift their more pessimistic story in ways that are very different from the consensus view.

Explore 4 other fair value estimates on UroGen Pharma - why the stock might be worth over 10x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your UroGen Pharma research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free UroGen Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate UroGen Pharma's overall financial health at a glance.

Want Some Alternatives?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Explore 30 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• The latest GPUs need a type of rare earth metal called Terbium and there are only 27 companies in the world exploring or producing it. Find the list for free.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.